EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Stefan Schreiber iD, Raymond K Cross, Remo Panaccione iD, Geert D'Haens, Peter Bossuyt, Iris Dotan, Jean-Frederic Colombel iD, Edouard Louis iD, Marla C Dubinsky iD, Kristina Kligys, Ezequiel Neimark, Alexandra Song und 5 weitere

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18184 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Stefan Schreiber und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Severity of Illness Index. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risankizumab is efficacious and well tolerated in adults with moderately to severely active Crohn's disease (CD).

Aim

To evaluate the corticosteroid‐sparing effect of risankizumab in CD.

Methods

During the 12‐week induction period, patients maintained stable baseline corticosteroid doses, up to 20 mg/day prednisone or equivalent. At week 0 of maintenance, a mandatory corticosteroid taper was started. This post hoc analysis evaluated corticosteroid‐free clinical and endoscopic outcomes at week 52 of maintenance; safety was also assessed.

Results

Of 889 patients randomised to induction with risankizumab 600 mg or placebo, 285 (32.1%) were taking baseline concomitant corticosteroids. Week 12 clinical remission and endoscopic response rates were greater for risankizumab 600 mg versus placebo, regardless of concomitant corticosteroid use. At week 52, 66.7%, 50.0% and 41.2% of patients taking risankizumab 180 mg, risankizumab 360 mg and (withdrawal) placebo, respectively, discontinued corticosteroids. Week 52 corticosteroid‐free clinical remission per stool frequency/abdominal pain score (risankizumab 180 mg [42.7%] or 360 mg [49.8%]; [withdrawal] placebo [39.0%]), corticosteroid‐free clinical remission per Crohn's Disease Activity Index (risankizumab 180 mg [51.0%] or 360 mg [49.5%]; [withdrawal] placebo [40.2%]), and corticosteroid‐free endoscopic response (risankizumab 180 mg [44.6%] or 360 mg [44.7%]; [withdrawal] placebo [20.7%]) rates were greater for risankizumab than placebo. Adverse event rates were generally similar, regardless of baseline corticosteroid use.

Conclusions

Efficacy of risankizumab 600 mg induction therapy was independent of concomitant corticosteroid use. Risankizumab 180 and 360 mg maintenance therapy yielded high rates of corticosteroid‐free clinical and endoscopic outcomes at week 52.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, MonoclonalSeverity of Illness IndexHumansMaleAdultFemaleTreatment OutcomeMiddle AgedDouble-Blind MethodAdrenal Cortex HormonesYoung AdultRemission InductionPrednisone

Substanzen

risankizumabAntibodies, MonoclonalAdrenal Cortex HormonesPrednisone

Autor:innen und Institutionen

  • Department Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
  • Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Alberta, Canada.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.

ORCID-Profile: Stefan Schreiber, Remo Panaccione, Jean-Frederic Colombel, Edouard Louis, Marla C Dubinsky, Marc Ferrante

Zitieren

APA

Schreiber, S., Cross, R. K., Panaccione, R., D'Haens, G., Bossuyt, P., Dotan, I., Colombel, J. F., Louis, E., Dubinsky, M. C., Kligys, K., Neimark, E., Song, A., Zambrano, J., Kalabic, J., Cheng, E., Zhang, Y., & Ferrante, M. (2024). Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18184

Vancouver

Schreiber S, Cross RK, Panaccione R, D'Haens G, Bossuyt P, Dotan I, et al. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18184

BibTeX
@article{Schreiber2024,
  author = {Schreiber, Stefan and Cross, Raymond K and Panaccione, Remo and D'Haens, Geert and Bossuyt, Peter and Dotan, Iris and Colombel, Jean-Frederic and Louis, Edouard and Dubinsky, Marla C and Kligys, Kristina and Neimark, Ezequiel and Song, Alexandra and Zambrano, Javier and Kalabic, Jasmina and Cheng, Erica and Zhang, Yafei and Ferrante, Marc},
  title = {Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18184}
}
Kostenlos starten →